Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial
Journal of thoracic oncology（2023）
关键词
Immunotherapy,PD-1,Camrelizumab,Chemo-therapy,Nonsquamous non-small cell lung cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要